H.C. Wainwright analyst Douglas Tsao is not that surprised that shares of Minerva Neurosciences came under pressure yesterday after the company disclosed a cyber-attack on a vendor delayed completion of enrollment for roluperidone and that the Phase 3 trial is now expected to readout in the first half of 2020. However, another "strong data set for seltorexant should have been enough to carry the day," Tsao tells investors in a research note partially titled "Missing the Forest for the Trees as Seltorexant Shines Again." While the data released by the company was not powered for statistical significance, it added "another impressive piece to the body of evidence supporting its utility," contends the analyst. Further, Tsao says that while pushing back roluperidone's readout is a disappointment, the news "doesn't fundamentally change things" since Minerva is capitalized into mid-2021 and the drug's new drug application submission has not been meaningfully impacted. The analyst reiterates a Buy rating on Minerva with a $22 price target.